Research Analysts Offer Predictions for SLDB FY2030 Earnings

Posted by Francis Steltz on Jun 4th, 2026

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Stock analysts at HC Wainwright raised their FY2030 earnings estimates for Solid Biosciences in a report released on Wednesday, June 3rd. HC Wainwright analyst A. He now forecasts that the company will earn $1.88 per share for the year, up from their prior estimate of $1.81. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($1.81) per share.

Solid Biosciences (NASDAQ:SLDB – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12).

Several other equities research analysts have also recently issued reports on SLDB. Wall Street Zen cut shares of Solid Biosciences from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Piper Sandler reiterated an “overweight” rating and issued a $18.00 target price (up from $17.00) on shares of Solid Biosciences in a report on Wednesday, May 13th. JPMorgan Chase & Co. increased their price objective on shares of Solid Biosciences from $11.00 to $12.00 and gave the company an “overweight” rating in a research report on Wednesday, March 25th. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. Finally, Chardan Capital restated a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Solid Biosciences has an average rating of “Moderate Buy” and an average price target of $16.82.

View Our Latest Analysis on Solid Biosciences

Solid Biosciences Trading Up 4.1%

Solid Biosciences stock opened at $6.85 on Thursday. Solid Biosciences has a 12-month low of $3.41 and a 12-month high of $8.87. The stock has a market cap of $674.38 million, a P/E ratio of -3.51 and a beta of 2.43. The company has a 50-day moving average price of $7.41 and a 200 day moving average price of $6.49.

Institutional Investors Weigh In On Solid Biosciences

Several hedge funds have recently modified their holdings of SLDB. Perceptive Advisors LLC lifted its holdings in shares of Solid Biosciences by 0.6% during the 1st quarter. Perceptive Advisors LLC now owns 11,906,646 shares of the company’s stock worth $85,728,000 after acquiring an additional 73,107 shares during the period. Bank of America Corp DE lifted its holdings in shares of Solid Biosciences by 12.3% during the 1st quarter. Bank of America Corp DE now owns 386,793 shares of the company’s stock worth $2,785,000 after acquiring an additional 42,499 shares during the period. Stempoint Capital LP purchased a new position in shares of Solid Biosciences during the 1st quarter worth about $1,407,000. Janus Henderson Group PLC purchased a new position in shares of Solid Biosciences during the 1st quarter worth about $28,877,000. Finally, Ally Bridge Group NY LLC lifted its holdings in shares of Solid Biosciences by 85.4% during the 1st quarter. Ally Bridge Group NY LLC now owns 766,974 shares of the company’s stock worth $5,522,000 after acquiring an additional 353,349 shares during the period. 81.46% of the stock is owned by institutional investors and hedge funds.

About Solid Biosciences

(Get Free Report)

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.